Immunotherapy in prostate cancer: challenges and opportunities.

abstract：:Rituximab is a chimeric monoclonal antibody used to treat hematologic and autoimmune diseases by depleting CD20-expressing B cells. Patients may develop hypogammaglobulinemia following treatment, with some demonstrating failure of B-cell recovery. The true frequency of hypogammaglobulinemia and/or impaired B-cell reco...

journal_title：Immunotherapy

authors： Sacco KA,Abraham RS

更新日期：2018-06-01 00:00:00

abstract：:Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein ef...

journal_title：Immunotherapy

authors： He Y,Hong Y,Mizejewski GJ

更新日期：2014-01-01 00:00:00

abstract：AIM:Placenta specific 1 (PLAC1) is a protein rarely expressed in normal cells, except it is important for placental development, with a possible role in the establishment of the mother-fetus interface. The gene is also highly active in a wide variety of cancers and therefore, immunization with PLAC1 peptides could poss...

journal_title：Immunotherapy

authors： Liso A,Massenzio F,Stracci F

更新日期：2017-05-01 00:00:00

abstract：:Evaluation of: Pujol-Autonell I, Ampudia RM, Monge P et al. Immunotherapy with tolerogenic dendritic cells alone or in combination with rapamycin does not reverse diabetes in NOD mice. ISRN Endocrinol. doi:10.1155/2013/346987 (2013) (Epub ahead of print). Many reports confirm that dendritic cells (DCs) can prevent aut...

journal_title：Immunotherapy

authors： Giannoukakis N

更新日期：2013-06-01 00:00:00

abstract：:Aim: Autologous hematopoietic stem cell transplantation (ASCT) is the standard-of-care curative treatment for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL), but the relapse rate is usually high. Materials & methods: In this study, we treated 14 RR-DLBCL patients by combining ASCT and anti-CD19 chimer...

journal_title：Immunotherapy

authors： Wang T,Gao L,Wang Y,Zhu W,Xu L,Wang Y,Yue W,Tang G,Chen L,Chen J,Zhang W,Yu X,Feng D,Yang J

更新日期：2020-09-01 00:00:00

abstract：:Systemic lupus erythematosus is a systemic autoimmune disease characterized by the presence of myriad autoantibodies, some with pathogenic potential, and diverse clinical manifestations. Involvement of the kidney is a major cause of morbidity and mortality in human lupus patients and in murine models of the disease. I...

journal_title：Immunotherapy

authors： Tagoe C,Putterman C

更新日期：2012-04-01 00:00:00

abstract：:It is now well established that the healthy bronchial tree contains a microbiome distinct from that of the upper respiratory tract and that the lung microbiome may be dysregulated in individuals with a chronic respiratory disease, such as asthma. In addition, after birth, gut microbes interact with the host tissue, es...

journal_title：Immunotherapy

authors： Pisi G,Fainardi V,Aiello M,Bertorelli G,Crisafulli E,Chetta A

更新日期：2017-11-01 00:00:00

abstract：:Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years. Improved t...

journal_title：Immunotherapy

authors： Valladares IG,Espinoza LR

更新日期：2009-09-01 00:00:00

abstract：:Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to trea...

journal_title：Immunotherapy

authors： Aya F,Fernández-Martínez A,Gaba L,Victoria I,Tosca M,Carrera C,Prat A,Arance A

更新日期：2016-06-01 00:00:00

abstract：:Epstein-Barr virus (EBV) infection is associated with a range of human malignancies of lymphocytic and epithelial cell origin. In addition to viral-mediated and genetic oncogenic events that lead to the establishment of EBV-associated malignancies, defects in the immune control of EBV likely play a significant role in...

journal_title：Immunotherapy

authors： Smith C,Khanna R

更新日期：2015-01-01 00:00:00

abstract：:Evaluation of: Turksma AW, Bontkes HJ, Ruizendaal JJ et al. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J. Transl. Med. 11, 152-165 (2013). Survivin has been identified to be an inhibitor of apoptosis and is highly expressed in many cancers. A number o...

journal_title：Immunotherapy

authors： Lee WT

更新日期：2013-11-01 00:00:00

abstract：:Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...

journal_title：Immunotherapy

authors： Huang J,Rong L,Wang E,Fang Y

更新日期：2021-01-01 00:00:00

abstract：:Hereditary angioedema (HAE) is a relatively rare autosomal dominant disorder that is typically characterized by recurrent episodes of edema in various body locations. It is most commonly caused by an inherited deficiency of functionally active C1 esterase inhibitor (C1-INH). Replacement therapy with a human plasma-der...

journal_title：Immunotherapy

authors： Bork K

更新日期：2014-01-01 00:00:00

abstract：:Aim: To investigate whether and how CD4+ T cells contribute to ILC2 activation during respiratory syncytial virus (RSV) infection. Methods: The methods of flow cytometry, quantitative PCR and ELISA were used in the present study. Results: Depletion of CD4+ T cells diminished the numbers of lung ILC2s as well as their ...

journal_title：Immunotherapy

authors： Han X,Bai S,Cui Y,Zhu W,Zhao N,Liu B

更新日期：2019-10-01 00:00:00

abstract：:Heat-shock proteins (HSPs) have been involved in different functions including chaperone activity, protein folding, apoptosis, autophagy and immunity. The HSP families have powerful effects on the stimulation of innate immune responses through Toll-like receptors and scavenger receptors. Moreover, HSP-mediated phagocy...

journal_title：Immunotherapy

authors： Milani A,Basirnejad M,Bolhassani A

更新日期：2019-02-01 00:00:00

abstract：:In spite of the considerable successes that have been achieved in the treatment of chronic myeloid leukemia (CML), cure for the disease can only be obtained by the present means in a rather small minority of patients. During the past decade, considerable progress has been made in the understanding of the immunology of...

journal_title：Immunotherapy

authors： Vonka V

更新日期：2010-03-01 00:00:00

abstract：:Over the last two decades, anti-CD20 monoclonal antibody (mAb) therapy has improved patient outcome in B-cell malignancies, and confirmed CD20 as an important target in chronic lymphocytic leukemia (CLL). Until recently, the gold standard was based on the utilization of rituximab combined with chemotherapy (fludarabin...

journal_title：Immunotherapy

authors： Bagacean C,Zdrenghea M,Tempescul A,Cristea V,Renaudineau Y

更新日期：2016-05-01 00:00:00

abstract：:Tumor-associated macrophages (TAMs), representing most of the leukocyte population in solid tumors, demonstrate great phenotypic heterogeneity and diverse functional capabilities under the influence of the local tumor microenvironment. These anti-inflammatory and protumorigenic macrophages modulate the local microenvi...

journal_title：Immunotherapy

authors： Petty AJ,Yang Y

更新日期：2017-03-01 00:00:00

abstract：:Evaluation of: Li F, Song D, Lu Y, Zhu H, Chen Z, He X. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy. J. Immunother. 36(3), 208-214 (2013). The association of EBV with a number of human maligna...

journal_title：Immunotherapy

authors： Smith C

更新日期：2013-08-01 00:00:00

abstract：:Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. I...

journal_title：Immunotherapy

authors： Muccioli M,Longstaff C,Benencia F

更新日期：2012-05-01 00:00:00

abstract：:Hematopoietic stem cell transplantation is the treatment of choice for many hematologic malignancies and genetic diseases. However, viral infections continue to account for substantial post-transplant morbidity and mortality. While antiviral drugs are available against some viruses, they are associated with significan...

journal_title：Immunotherapy

authors： Tzannou I,Leen AM

更新日期：2015-01-01 00:00:00

abstract：:γδ T cells are capable of recognizing tumor cells and exert potent cellular cytotoxicity against a large range of tumors, including colon cancer. However, tumors utilize numerous strategies to escape recognition or killing by patrolling γδ T cells, such a downregulation of NKG2D ligands, MICA/B and ULBPs. Therefore, t...

journal_title：Immunotherapy

authors： Ramutton T,Buccheri S,Dieli F,Todaro M,Stassi G,Meraviglia S

更新日期：2014-01-01 00:00:00

abstract：:Rheumatoid arthritis (RA) is a chronic inflammatory disease in which persistent inflammation of synovial tissue results in a progressive functional decline of the joint and premature mortality. TNF inhibitors were the first biological disease-modifying antirheumatic drugs (DMARDs) used to treat RA. Since then, new bio...

journal_title：Immunotherapy

authors： García-Hernández MH,González-Amaro R,Portales-Pérez DP

更新日期：2014-01-01 00:00:00

abstract：:The era of active immunotherapy has now been successfully ushered into the clinical realm of advanced prostate cancer. The successful clinical trial development and US FDA approval of sipuleucel-T (Provenge®) has revamped the therapeutic paradigm for advanced prostate cancer. Nonetheless, physician and patient educati...

journal_title：Immunotherapy

authors： Shore ND

更新日期：2011-08-01 00:00:00

abstract：:Aim: Previously, we constructed a novel anti-p21Ras single-chain antibody fragment, KGH-R1-single-chain fragment variant (ScFv). However, the immunoreactivity of this antibody toward p21Ras is still unclear. Materials & methods: ELISAs, immunohistochemistry, western blotting and immunofluorescence were used to identif...

journal_title：Immunotherapy

authors： Wang P,Pan X,Feng Q,Zou H,Cui J,He Y,Luo Y,Yang J

更新日期：2020-08-01 00:00:00

abstract：:Bacillus Calmette-Guérin and other mycobacterial vaccines are important therapeutic methods in a series of chronic inflammatory disorders characterized by Th1/Th2 imbalance in which Th2 type cells and cytokines often increase. However, few studies have investigated whether it can reduce or prevent the symptoms and att...

journal_title：Immunotherapy

authors： Ming M,Li C,Luo Z,Lv S

更新日期：2013-02-01 00:00:00

abstract：:Taking advantage of the cellular immune system is the mainstay of the adoptive cell therapy, to induce recognition and destruction of cancer cells. The impressive demonstration of this principle is chimeric antigen receptor-modified T (CAR-T)-cell therapy, which had a major impact on treating relapsed and refractory h...

journal_title：Immunotherapy

authors： El-Khazragy N,Ghozy S,Emad P,Mourad M,Razza D,Farouk YK,Mohamed NA,Ahmed MK,Youssef T,Bahnasawy YM,Elmasery S

更新日期：2020-12-01 00:00:00

abstract：:Immunotherapy holds a highly promising treatment approach for metastatic melanoma patients. Adoptive cell transfer (ACT) involves the ex vivo expansion of autologous antitumor reactive lymphocytes and their reinfusion into lymphodepleted patients, accompanied by IL-2 administration. ACT with tumor-infiltrating T lymph...

journal_title：Immunotherapy

authors： Itzhaki O,Levy D,Zikich D,Treves AJ,Markel G,Schachter J,Besser MJ

更新日期：2013-01-01 00:00:00

abstract：:Renal toxicity from immune checkpoint inhibitors (ICIs) is an increasingly recognized cause of acute kidney injury among patients with cancer. ICI-associated acute kidney injuries typically present as acute interstitial nephritis and the timing of onset is highly variable. Herein, we present a case of a patient with r...

journal_title：Immunotherapy

authors： Mulroy M,Ghafouri S,Sisk A,Ribas A,Goshtaseb R,Cherry G,Shen J

更新日期：2021-03-01 00:00:00

abstract：:Evaluation of: Boudousq V, Ricaud S, Garambois V et al.: Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing (125)I-labeled monoclonal antibodies. J. Nucl. Med. 51, 1748-1755 (2010). Mesothelioma, pseudomyxoma peritonei, ovarian and colon cancers, and s...

journal_title：Immunotherapy

authors： Baranowska-Kortylewicz J

更新日期：2011-04-01 00:00:00